Results 51 to 60 of about 22,351 (243)

The effect of Fingolimod on patients with moderate to severe COVID‐19

Pharmacology Research & Perspectives, 2022
Hyper‐inflammation, cytokine storm, and recruitment of immune cells lead to uncontrollable endothelial cell damage in patients with coronavirus disease 2019 (COVID‐19).
S. Teymouri, Siamak Pourbayram Kaleybar, Seyyed Sina Hejazian, Seyyedeh Mina Hejazian, K. Ansarin, M. Ardalan, S. Zununi Vahed   +6 more
semanticscholar   +1 more source

Effects of fingolimod on heart injury induced by renal ischemia-reperfusion [PDF]

مجله پزشکی دانشگاه علوم پزشکی تبریز
Background. Renal ischemia-reperfusion injury (IRI) is one of the inevitable complications of surgery. The evidence shows that fingolimod, with its anti-inflammatory effects, can play a protective role in renal IRI.
Bahram Niknafs, Yasin Bagheri, Seyyedeh Mina Hejazian, Parya Niknafs, Neda Roshanravan, Mohammadreza Ardalan, Sepideh Zununi Vahed   +6 more
doaj   +1 more source

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study

Journal of Neurology, 2022
Exit strategy after natalizumab cessation in multiple sclerosis (MS) is a crucial point because the risk of disease reactivation is high during this period.
K. Bigaut, L. Kremer, Thibaut Fabacher, G. Ahle, Mathilde Goudot, M. Fleury, C. Gaultier, S. Courtois, N. Collongues, J. de Seze   +9 more
semanticscholar   +1 more source

Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis

, 2015
Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability.
A. Ghazaryan, Rossini, Paolo Maria, S. Vollaro, Mulas, Delia, P. M. Rossini, Pasqualetti, Patrizio, D. Mulas, D. Landi, G. Pellegrino, E. Falato, P. Pasqualetti, M. M. Filippi   +11 more
core   +1 more source

Fingolimod effects on the brain are mediated through biochemical modulation of bioenergetics, autophagy, and neuroinflammatory networks

Proteomics, 2022
Fingolimod (FTY720) is an oral drug approved by the Food and Drug Administration (FDA) for management of multiple sclerosis (MS) symptoms, which has also shown beneficial effects against Alzheimer's (AD) and Parkinson's (PD) diseases pathologies ...
M. Mirzaei, M. Abyadeh, Anita J. Turner, R. Wall, Joel M. Chick, J. Paulo, Veer Gupta, D. Basavarajappa, Nitin Chitranshi, S. Mirshahvaladi, Yuyi You, Matthew J. Fitzhenry, A. Amirkhani, P. Haynes, A. Klistorner, Vivek Gupta, Stuart L. Graham   +16 more
semanticscholar   +1 more source

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series

BMC Neurology, 2021
Background Fingolimod is a S1P1 receptor modulator that prevents activated lymphocyte egress from lymphoid tissues causing lymphopenia, mainly affecting CD4+ T lymphocytes.
Silvia Delgado, Jeffrey Hernandez, Leticia Tornes, Kottil Rammohan   +3 more
doaj   +1 more source

Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis

Neurology
Background and Objectives Patients with pediatric-onset multiple sclerosis (POMS) typically experience higher levels of inflammation with more frequent relapses, and though patients with POMS usually recover from relapses better than adults, patients ...
T. Spelman, Gabrielle Simoneau, Robert Hyde, R. Kuhelj, R. Alroughani, S. Ozakbas, R. Karabudak, B. Yamout, S. Khoury, M. Terzi, C. Boz, D. Horáková, E. Kubala Havrdová, Bianca Weinstock-Guttman, F. Patti, A. Altintas, S. Mrabet, R. Gouider, J. Inshasi, V. Shaygannejad, S. Eichau, W. Ward, H. Butzkueven   +22 more
semanticscholar   +1 more source

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

Journal of Neurology, 2021
Background Recent observations suggest a lack of humoral response after SARS-CoV-2 vaccination in multiple sclerosis (MS) patients treated with fingolimod or ocrelizumab Objectives To assess serological response to SARS-CoV-2 vaccination in MS patients ...
Guerrieri S., Lazzarin S., Zanetta C., Nozzolillo A., Filippi M., M. L.   +5 more
semanticscholar   +1 more source

The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary

PLoS ONE, 2022
Background Fingolimod was approved and reimbursed by the healthcare provider in Hungary for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS) in 2012.
T. Biernacki, Dániel Sandi, J. Füvesi, Z. Fricska-Nagy, T. Kincses, P. Ács, C. Rózsa, Enikő Dobos, B. Cseh, L. Horváth, Zsuzsanna Nagy, A. Csányi, K. Kovács, T. Csépány, L. Vécsei, K. Bencsik   +15 more
semanticscholar   +1 more source

Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis [PDF]

, 2018
BACKGROUND AND PURPOSE: In 2011, fingolimod was approved in Switzerland for the treatment of relapsing-remitting multiple sclerosis (RRMS). The aim of the present study was to assess the effectiveness and retention of fingolimod in a real-life Swiss ...
C. P. Kamm, A. Baumann, O. Findling, C. Zecca, Findling, O., Kamm, Christian Philipp, Baumann, A., Lalive, P. H., Czaplinski, A., Roth, S., A. Czaplinski, Perriard, G., Bachmann, V., S. Roth, Pless, M. L., G. Perriard, P. H. Lalive, V. Bachmann, Zecca, C., M. L. Pless   +19 more
core   +1 more source